Committee
John Warren Davis, MD; Eastern Virginia Medical School, Norfolk, VA (Chair)
Peter Earl Clark, MD; Wake Forest University Baptist Medical Center, Winston-Salem, NC
Jonathan Andrew Coleman, MD; National Cancer Institute, Bethesda, MD
Jeffrey Maxwell Holzbeierlein, MD; Kansas University Medical Center, Kansas City, KS
Daniel Wei Lin, MD; University of Washington, Seattle, WA
Douglas S. Scherr, MD; Cornell University, New York, NY
John Francis Ward III, MD; Nevada Cancer Center, Las Vegas, NV

THURSDAY, DECEMBER 1, 2005

6:30 p.m. – 9:30 p.m.     Young Urologic Oncologists’ Dinner: The Surgeon Scientist – Is it Feasible?
Balancing the Academic with the Clinical
Speaker: Robert Uzzo, MD, Fox Chase Cancer Center
Location: Hyatt Regency Bethesda

Objectives
At the end of this discussion, the participants should be able to:
1. Identify barriers to the surgeon scientist and strategies to overcome them.
2. Identify developmental schemes for the aspiring young urologic oncologist interested in clinical and scientific pursuits.

7:00 p.m. – 8:30 p.m.     Young Urologic Oncologists (Y.U.O.) Podium Presentations
Moderator: John Davis, MD, Eastern Virginia Medical School

7:00 p.m.       BODY MASS INDEX AND IMPACT ON PSA SCREENING AND PROSTATE CANCER DETECTION IN THE PLCO TRIAL
Robert Grubb, MD, David Levin, MD, Paul Pinsky, PhD, Jerome Mabie, Thomas Riley, Robert Greenlee, PhD, Donald Urban, MD, Lawrence Ragard, MD, E. David Crawford, MD and Gerald Andriole, MD (Presented By: Robert Grubb, MD)

7:10 p.m.       A PHASE I/II PROSPECTIVE DOSE ESCALATING TRIAL OF LYCOPENE IN PATIENTS WITH BIOCHEMICAL RELAPSE OF PROSTATE CANCER FOLLOWING DEFINITIVE LOCAL THERAPY
Peter Clark, MD, M. Craig Hall, MD, Lester Borden, MD, Antonius Miller, MD, Jennifer Hu, PhD, W. Robert Lee, MD, Ralph D’Agostino, PhD, James Lovato, Michelle Harmon and Frank Torti, MD (Presented By: Peter Clark, MD)

7:20 p.m.       QUANTIFYING THE PUBLIC HEALTH IMPACT OF LOW HOSPITAL VOLUME ON OUTCOMES FOLLOWING CANCER SURGERY
Brent Hollenbeck, MD, MS, David Miller, MD, David Taub, MD, Rodney Dunn, MS and John Wei, MD, MS (Presented By: Brent Hollenbeck, MD, MS)

7:30 p.m.       BRANCHING PHENOTYPE OF RENAL CELL CARCINOMA IS ABROGATED BY NOX4 SILENCING
Jodi Maranchie, MD and Ye Zhan (Presented By: Jodi Maranchie, MD)

7:40 p.m.       RISK OF DEATH DUE TO PROSTATE CANCER AND COMPETING CAUSES AMONGST AFRICAN AMERICAN MEN CHOOSING WATCHFUL WAITING
Ash K Tewari, George Divine and Mani Menon (Presented By: Ash K Tewari)
7:50 p.m.  EXTENDED VS. LIMITED LAPAROSCOPIC PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: THE VALUE OF PARTIN TABLES IN SELECTION OF THE NEED FOR AND THE EXTENT OF DISSECTION  Karim Touijer, MD, Farhang Rabbani, MD, Javier Romero, MD and Bertrand Guillonneau, MD (Presented By: Karim Touijer, MD)

8:00 p.m.  RISK OF DIABETES MELLITUS IN MEN UNDERGOING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER  Ithaar Derweesh, MD, Matt Kincade, MD, John Malcolm, MD, Kimberly Lamar, PhD, Anthony Patterson, MD, Abbas Kitabchi, MD, PhD and Robert Wake, MD (Presented By: Ithaar Derweesh, MD)

8:10 p.m.  REDOX REGULATION OF INVASION AND MIGRATION IN BLADDER CANCER  Badar Mian, MD, James Belarmino, MD, Xiao Fang Ha and J. Andre Melendez, PhD (Presented By: Badar Mian, MD)

8:20 p.m.  IMPACT OF FLUORESCENT IN SITU HYBRIDIZATION OF RENAL TUMORS AND HISTOPATHOLOGIC DIAGNOSIS  Michael Franks, MD (Presented By: Michael Franks, MD)

8:30 p.m.  PATTERNS OF CARE FOR MEN WITH PROSTATE CANCER FOLLOWING FAILURE OF PRIMARY TREATMENT  Tracey Krupski, MD, MPH, Christopher Saigal, MD, MPH, Janet Hanley, MS and Mark Litwin, MD, MPH (Presented By: Tracey Krupski, MD, MPH)

8:45 p.m. – 9:00 p.m.  The Surgeon Scientist – Is It Feasible? Balancing the Academic with the Clinical  Invited Speaker: Robert Guy Uzzo, MD – Fox Chase Cancer Center, Philadelphia, PA

FRIDAY, DECEMBER 2, 2005

2:30 p.m. – 3:00 p.m.  Young Urologic Oncologists (Y.U.O.) Podium Presentations  Moderator: John Davis, MD – Eastern Virginia Medical School

2:30 p.m.  THE NATURAL HISTORY OF RESIDUAL AND RECURRENT DISEASE FOLLOWING RENAL ABLATIVE THERAPY: A MULTI-INSTITUTIONAL STUDY  Surena Matin, MD, Kamran Ahrar, MD, Jeffrey Cadeddu, MD, Debra Gervais, MD, Francis McGovern, MD, Ronald Zangoria, MD, Robert Uzzo, MD, John Haaga, MD, Martin Resnick, MD and Inderbir Gill, MD (Presented By: Surena Matin, MD)

2:40 p.m.  PERIOPERATIVE QUALITY CARE INDICATORS OF RETROPUBIC, LAPAROSCOPIC, AND ROBOTIC PROSTATECTOMY: RESULTS FROM A NATIONAL, MULTI-CENTER, PROSPECTIVE COHORT  Jim Hu, MD, MPH, David Wood, MD, Gerald Andriole, MD, Rodney Dunn, PhD, Mark Litwin, MD, MPH, Louis Pisters, MD, Eric Klein, MD, James Montie, MD, John Wei, MD, MPH and Martin Sanda, MD (Presented By: Jim Hu, MD, MPH)

2:50 p.m.  GENOME-WIDE ASSOCIATION STUDY FOR PROSTATE CANCER USING THE AFFECTMEX 10K GENECHIP AND EVALUATION OF SUSCEPTIBILITY GENES FOR PROSTATE CANCER IN A CLINICAL SETTING  Robert Nam, MD, MSc, William Zhang, MD, PhD, Laurence Klotz, MD, John Trachtenberg, MD, Michael Jewett, MD, Steven Narod, MD, Robert Nam, MD, MSc, William Zhang, MD, PhD, Laurence Klotz, MD, John Trachtenberg, MD, Michael Jewett, MD and Steven Narod, MD (Presented by Robert Nam, MD, MSc)